#techthatmatters

This Antibody Drug Could Reduce 45% of Deaths of COVID-19 Patients on Ventilators

This Antibody Drug Could Reduce 45% of Deaths of COVID-19 Patients on Ventilators

Doctors at the University of Michigan discovered an antibody-drug that could significantly reduce the chance of death of COVID-19 patients who are on a ventilator, according to the MIT Technology Review. Given the grim statistics, that more than half of COVID-19 patients will die on a ventilator, this drug could be a vital turning point for those fighting for their lives.

The doctors’ goal was “to control the haywire immune reaction” that pushes some COVID-19 patients to the brink of death. So, they administered the drug, tocilizumab, “which blocks IL-6, a molecule in the body that sets off a reaction to an infection” to 78 patients on ventilators.



This resulted in 45% of the patients who received the drug were less likely to die than those who didn’t receive it. However, there is a major caveat – the doctors were aware of which patients got the drug and which didn’t. Therefore, there could have been a bias in the selection of those patients who received the drug. Some patients could be more likely to improve than others. (More studies will follow.)

We respect your privacy.